We are live on
!
Find out more
RCMNY
Rubric Capital Management (New York) Portfolio holdings
AUM
$9.44B
1-Year Est. Return
68.42%
This Fund
S&P 500
This Quarter
Est. Return
+6.05%
1 Year Est. Return
+68.42%
3 Year Est. Return
+212.09%
5 Year Est. Return
+270.59%
10 Year Est. Return
–
AUM
$2.34B
AUM Growth
-$1.52B
(-39%)
Cap. Flow
-$1.58B
Cap. Flow
% of AUM
-67.74%
Top 10 Holdings %
Top 10 Hldgs %
43.48%
Holding
80
New
9
Increased
13
Reduced
27
Closed
18
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$115M |
| 2 |
Viatris
VTRS
|
+$114M |
| 3 |
Magnite
MGNI
|
+$24.6M |
| 4 |
NRG Energy
NRG
|
+$23.4M |
| 5 |
Arcutis Biotherapeutics
ARQT
|
+$15.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Scorpio Tankers
STNG
|
+$67.8M |
| 2 |
Cameco
CCJ
|
+$56.1M |
| 3 |
First Citizens BancShares
FCNCA
|
+$51.6M |
| 4 |
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
|
+$37.6M |
| 5 |
Cimpress
CMPR
|
+$29.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 33.22% |
| 2 | Energy | 14.33% |
| 3 | Industrials | 13.82% |
| 4 | Financials | 10.76% |
| 5 | Utilities | 7.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Arbutus Biopharma
ABUS
$895M
| $7.81M | 0.33% |
3,395,855
-799,217
| -19% | -$2.08M |
|
52
Cullinan Oncology
CGEM
$1.26B
| $6.75M | 0.29% |
626,929
| – | – |
|
53
Werewolf Therapeutics
HOWL
$18M
| $5.9M | 0.25% |
1,935,357
| – | – |
|
|
BCYC
54
Bicycle Therapeutics
BCYC
$288M
| $5.24M | 0.22% |
205,423
| – | – |
|
55
TherapeuticsMD
TXMD
$24M
| $4.91M | 0.21% |
1,192,191
| – | – |
|
56
OmniAb
OABI
$494M
| $3.53M | 0.15% |
+702,053
| New | +$2.85M |
|
57
PENN Entertainment
PENN
$2.57B
| $3.3M | 0.14% |
+137,428
| New | +$3.66M |
|
58
PUT
Virgin Galactic
SPCE
$490M
| $2.33M | 0.1% |
+30,000
| New | +$2.38M |
|
|
PNT
59
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $1.72M | 0.07% |
190,000
-2,455,336
| -93% | -$21.7M |
|
60
Karyopharm Therapeutics
KPTI
$47.1M
| $1.65M | 0.07% |
61,280
-234,790
| -79% | -$10.1M |
|
|
VINC
61
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
| $461K | 0.02% |
17,719
-1,617
| -8% | -$46.3K |
|
|
FREE
62
DELISTED
Whole Earth Brands, Inc. Class A Common Stock
FREE
| $285K | 0.01% |
70,985
-834,895
| -92% | -$2.33M |
|
63
Cellebrite
CLBT
$3.86B
| – | – |
-408,192
| Closed | -$2.49M |
|
|
64
Cimpress
CMPR
$2.33B
| – | – |
-664,475
| Closed | -$29.1M |
|
|
65
First Citizens BancShares
FCNCA
$25.5B
| – | – |
-53,058
| Closed | -$51.6M |
|
66
InterDigital
IDCC
$8.95B
| – | – |
-314,018
| Closed | -$22.9M |
|
67
PUT
iShares Russell 2000 ETF
IWM
$82B
| – | – |
-7,550,000
| Closed | -$1.35B |
|
68
Laureate Education
LAUR
$5.06B
| – | – |
-2,393,482
| Closed | -$28.1M |
|
69
Noble Corp
NE
$7.08B
| – | – |
-237,875
| Closed | -$9.39M |
|
70
Nerdy
NRDY
$95.9M
| – | – |
-2,601,118
| Closed | -$10.9M |
|
71
Outfront Media
OUT
$5.31B
| – | – |
-1,356,658
| Closed | -$21.7M |
|
72
Schrodinger
SDGR
$1.39B
| – | – |
-1,087,793
| Closed | -$28.6M |
|
73
Tarsus Pharmaceuticals
TARS
$3.07B
| – | – |
-221,488
| Closed | -$2.78M |
|
74
Xeris Biopharma Holdings
XERS
$1.55B
| – | – |
-426,267
| Closed | -$695K |
|
|
CMRX
75
DELISTED
Chimerix, Inc.
CMRX
| – | – |
-7,336,735
| Closed | -$9.24M |
|
Similar funds
RCM
SIM
NPT
AC
PVI
WPL
IAA
LAMI
Rubric Capital Management (New York)'s Q2 2023 Portfolio in Review
As of Q2 2023, Rubric Capital Management (New York) held 80 positions worth $2.34B, down 39% from $3.86B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Rubric Capital Management (New York) withdrew a net $1.58B in Q2 2023, closing 18 positions and reducing 27 holdings. Its most notable exit was First Citizens BancShares, an estimated $51.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 16% a quarter earlier, followed by Energy and Industrials.
Against the trend, Rubric Capital Management (New York) opened a new position in Viatris worth $119M.
- Rubric Capital Management (New York)'s largest Q2 2023 buy was Viatris: 11,950,000 shares worth $119M.
- Rubric Capital Management (New York) added most to Teva Pharmaceuticals in Q2 2023, an estimated $115M increase.
- Rubric Capital Management (New York)'s biggest Q2 2023 reduction was Scorpio Tankers, cutting an estimated $67.8M.
- Rubric Capital Management (New York) fully exited First Citizens BancShares in Q2 2023, selling an estimated $51.6M.
- Rubric Capital Management (New York)'s ten largest holdings make up 43% of its $2.34B portfolio in Q2 2023.
- Rubric Capital Management (New York) opened 9 new positions and closed 18 in Q2 2023.
- Rubric Capital Management (New York)'s portfolio value fell 39% quarter-over-quarter to $2.34B.
Based on Rubric Capital Management (New York)'s 13F filing for Q2 2023, filed 11 Aug 2023.